Fluidigm to Participate in the Cantor Virtual Global Healthcare Conference
September 02 2021 - 8:30AM
Fluidigm Corporation (Nasdaq:FLDM), an innovative
biotechnology tools provider with a vision to improve life through
comprehensive health insight, today announced that Chris
Linthwaite, President and CEO, and Vikram Jog, Chief Financial
Officer, will participate in investor meetings and present updates
regarding Fluidigm’s business strategy and financial performance at
the following investor event:
Cantor Virtual Global Healthcare
ConferenceTuesday, September 28, 2021Fluidigm presentation at 2:00
p.m. ET, 11:00 a.m. PT
A live webcast of the company’s presentation and subsequent
replay will be available in the Events &
Presentations section of the Fluidigm® investor website. The
webcast will be archived for 90 days following the live
presentation.
About Fluidigm
Fluidigm (Nasdaq:FLDM) focuses on the most pressing needs
in translational and clinical research, including cancer,
immunology, and immunotherapy. Using proprietary CyTOF® and
microfluidics technologies, we develop, manufacture, and market
multi-omic solutions to drive meaningful insights in health and
disease, identify biomarkers to inform decisions, and accelerate
the development of more effective therapies. Our customers are
leading academic, government, pharmaceutical, biotechnology, plant
and animal research, and clinical laboratories worldwide. Together
with them, we strive to increase the quality of life for all. For
more information, visit fluidigm.com.Patent information and
Limited Use Label License: Fluidigm.com/legal/notices. Fluidigm,
the Fluidigm logo, Advanta, and CyTOF are trademarks
and/or registered trademarks of Fluidigm Corporation or
its subsidiaries in the United States and/or other
countries. All other trademarks are the sole property of their
respective owners. The Advanta™ Dx SARS-CoV-2 RT-PCR Assay is for
In Vitro Diagnostic Use. It is for Use under Emergency Use
Authorization Only. Rx Only. Other Fluidigm products are
provided for Research Use Only. Not for use in diagnostic
procedures.
Available InformationWe use our website
(fluidigm.com), investor site (investors.fluidigm.com), corporate
Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm),
and LinkedIn page (linkedin.com/company/fluidigm-corporation) as
channels of distribution of information about our products, our
planned financial and other announcements, our attendance at
upcoming investor and industry conferences, and other matters. Such
information may be deemed material information, and we may use
these channels to comply with our disclosure obligations under
Regulation FD. Therefore, investors should monitor our website and
our social media accounts in addition to following our press
releases, SEC filings, public conference calls, and
webcasts.
Contacts:
Investors:Peter DeNardo415 389
6400ir@fluidigm.com
Media:Mark SpearmanSenior Director, Corporate
Communications650 243 6621mark.spearman@fluidigm.com
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Apr 2023 to Apr 2024